{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8","upperLimit":"22.1","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"The percentage of patients who achieve a complete response or partial response per Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST version 1.1), Complete Response (CR) = disappearance of all target lesions and non-target lesions, Partial Response (PR), \\>= 30% decrease in the sum of the longest diameter of target lesions with no progression in non-target lesions and no new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.\n\nCDX-3379 and cetuximab: Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.","id":"OG000","title":"CDX-3379 and Cetuximab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"The proportion of evaluable patients who achieve a best overall response of complete or partial response according to RECIST 1.1 assessed up to 24 months.","title":"Objective Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}